The DOI matches its Crossref record.
Allogeneic cell therapy bioprocess economics and optimization: Single‐use cell expansion technologies
Open accessAbstract
For allogeneic cell therapies to reach their therapeutic potential, challenges related to achieving scalable and robust manufacturing processes will need to be addressed. A particular challenge is producing lot‐sizes capable of meeting commercial demands of up to 10 9 cells/dose for large patient numbers due to the current limitations of expansion technologies. This article describes the application of a decisional tool to identify the most cost‐effective expansion technologies for different scales of production as well as current gaps in the technology capabilities for allogeneic cell therapy manufacture. The tool integrates bioprocess economics with optimization to assess the economic competitiveness of planar and microcarrier‐based cell expansion technologies. Visualization methods were used to identify the production scales where planar technologies will cease to be cost‐effective and where microcarrier‐based bioreactors become the only option. The tool outputs also predict that for the industry to be sustainable for high demand scenarios, significant increases will likely be needed in the performance capabilities of microcarrier‐based systems. These data are presented using a technology S‐curve as well as windows of operation to identify the combination of cell productivities and scale of single‐use bioreactors required to meet future lot sizes. The modeling insights can be used to identify where future R&D investment should be focused to improve the performance of the most promising technologies so that they become a robust and scalable option that enables the cell therapy industry reach commercially relevant lot sizes. The tool outputs can facilitate decision‐making very early on in development and be used to predict, and better manage, the risk of process changes needed as products proceed through the development pathway. Biotechnol. Bioeng. 2014;111: 69–83. © 2013 The Authors. Biotechnology and Bioengineering Published by Wiley Periodicals, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Scientific, sustainability and regulatory challenges of cultured meat
Post, M. J., Levenberg, S., Kaplan, D. L., Genovese, N., Fu, J., Bryant, C. J., Negowetti, N., Verzijden, K., & Moutsatsou, P. (2020) · Nature Food · doi:10.1038/s43016-020-0112-z · Cited by 783
Baradez, M.-O., Biziato, D., Hassan, E., & Marshall, D. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00047 · Cited by 55
Progress and challenges in developing allogeneic cell therapies
Deuse, T., & Schrepfer, S. (2025) · Cell Stem Cell · doi:10.1016/j.stem.2025.03.004 · Cited by 51
Wang, K., Liu, Y., Li, J., Wang, B., Bishop, R., White, C., Das, A., Levine, A. D., Ho, L., Levine, B. L., et al. (2019) · Cytotherapy · doi:10.1016/j.jcyt.2019.07.002 · Cited by 29
Stem cells and beta cell replacement therapy: a prospective health technology assessment study
Wallner, K., Pedroza, R. G., Awotwe, I., Piret, J. M., Senior, P. A., Shapiro, A. M. J., & McCabe, C. (2018) · BMC Endocrine Disorders · doi:10.1186/s12902-018-0233-7 · Cited by 19
“This stochastic model is based on a previous treatment model of type 1 diabetes [20] and the work by Simaria and colleagues [21].”
Metadata
- Authors
- Simaria, A. S., Hassan, S., Varadaraju, H., Rowley, J., Warren, K., Vanek, P., & Farid, S. S.
- Venue
- Biotechnology and Bioengineering
- Publisher
- Wiley
- Published
- 2013-08-16
- Volume
- 111
- Issue
- 1
- Pages
- 69-83
- ISSN
- 0006-3592 (ISSN-L)
- 1097-0290
- OpenAlex
- W1894559552
- Cited by
- 192
- References
- 0
- FWCI
- 6.64
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.